R&D Insights: How Sarepta Therapeutics, Inc. and Galapagos NV Allocate Funds

R&D Spending: A Tale of Two Biotechs

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Galapagos NV have demonstrated contrasting strategies in their R&D allocations.

From 2014 to 2023, Sarepta Therapeutics, Inc. has consistently increased its R&D expenses, peaking in 2023 with a staggering 878% increase from its 2014 spending. This aggressive investment underscores Sarepta's focus on advancing its pipeline of genetic medicine. In contrast, Galapagos NV's R&D spending saw a more moderate growth, with a notable peak in 2020, followed by a significant reduction in 2023, reflecting a strategic shift or potential restructuring.

These trends highlight the dynamic nature of biotech investments and the varying approaches companies take to drive innovation and maintain competitive advantage.